Novel blood test for early biomarkers of preeclampsia and Alzheimer's disease.

Autor: Cheng S; Department of Pediatrics, Women and Infants Hospital-Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence, RI, 02905, USA., Banerjee S; Department of Pediatrics, Women and Infants Hospital-Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence, RI, 02905, USA., Daiello LA; Department of Neurology, Warren Alpert Medical School of Brown University and Alzheimer's Disease and Memory Disorders Center At Rhode Island Hospital, Providence, RI, 02903, USA., Nakashima A; Department of Obstetrics and Gynecology, University of Toyama, Toyama, Japan., Jash S; Department of Pediatrics, Women and Infants Hospital-Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence, RI, 02905, USA., Huang Z; Department of Pediatrics, Women and Infants Hospital-Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence, RI, 02905, USA., Drake JD; Department of Neurology, Warren Alpert Medical School of Brown University and Alzheimer's Disease and Memory Disorders Center At Rhode Island Hospital, Providence, RI, 02903, USA., Ernerudh J; Department of Biomedical and Clinical Services, Linkoping University, Linkoping, Sweden., Berg G; Department of Biomedical and Clinical Services, Linkoping University, Linkoping, Sweden., Padbury J; Department of Pediatrics, Women and Infants Hospital-Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence, RI, 02905, USA., Saito S; Department of Obstetrics and Gynecology, University of Toyama, Toyama, Japan., Ott BR; Department of Neurology, Warren Alpert Medical School of Brown University and Alzheimer's Disease and Memory Disorders Center At Rhode Island Hospital, Providence, RI, 02903, USA., Sharma S; Department of Pediatrics, Women and Infants Hospital-Warren Alpert Medical School of Brown University, 101 Dudley Street, Providence, RI, 02905, USA. ssharma@wihri.org.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2021 Aug 05; Vol. 11 (1), pp. 15934. Date of Electronic Publication: 2021 Aug 05.
DOI: 10.1038/s41598-021-95611-5
Abstrakt: A non-invasive and sensitive blood test has long been a goal for early stage disease diagnosis and treatment for Alzheimer's disease (AD) and other proteinopathy diseases. We previously reported that preeclampsia (PE), a severe pregnancy complication, is another proteinopathy disorder with impaired autophagy. We hypothesized that induced autophagy deficiency would promote accumulation of pathologic protein aggregates. Here, we describe a novel, sensitive assay that detects serum protein aggregates from patients with PE (n = 33 early onset and 33 late onset) and gestational age-matched controls (n = 77) as well as AD in both dementia and prodromal mild cognitive impairment (MCI, n = 24) stages with age-matched controls (n = 19). The assay employs exposure of genetically engineered, autophagy-deficient human trophoblasts (ADTs) to serum from patients. The aggregated protein complexes and their individual components, including transthyretin, amyloid β-42, α-synuclein, and phosphorylated tau231, can be detected and quantified by co-staining with ProteoStat, a rotor dye with affinity to aggregated proteins, and respective antibodies. Detection of protein aggregates in ADTs was not dependent on transcriptional upregulation of these biomarkers. The ROC curve analysis validated the robustness of the assay for its specificity and sensitivity (PE; AUC: 1, CI: 0.949-1.00; AD; AUC: 0.986, CI: 0.832-1.00). In conclusion, we have developed a novel, noninvasive diagnostic and predictive assay for AD, MCI and PE.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje